Mammalian Polyclonal Igg Antibody Market Size & Share Analysis - Growth, Trends, And Forecasts (2024 - 2029)

Mammalian Polyclonal IgG Antibody Market Analysis

The Mammalian Polyclonal IgG Antibody Market size is estimated at USD 1.22 billion in 2024, and is expected to reach USD 1.56 billion by 2029, growing at a CAGR of 4.97% during the forecast period (2024-2029).

Mammalian polyclonal IgG antibodies are derived from mammals' blood serum (e.g., rabbits, goats, or mice) after hyperimmunization with specific antigens. These heterogeneous antibodies recognize multiple epitopes on the target antigen, leading to broad immune responses. The mammalian polyclonal IgG antibody market is experiencing dynamic growth fueled by growing demand for targeted therapies, increasing innovation in antibody modification, and facility expansion for antibody production by manufacturers.

The increasing development and application of mammalian IgG antibodies, particularly those that target specific cancer cells while minimizing off-target toxicity, significantly contribute to the growth of the mammalian polyclonal IgG antibodies market. For instance, a study published in the JCI Insight in December 2023 highlighted the efficacy of polyclonal antibodies (pAb) in promoting cancer cell lysis through mechanisms such as complement-dependent cytotoxicity (CDC), apoptosis, antibody-dependent cellular cytotoxicity (ADCC), and antibody-dependent cellular phagocytosis (ADCP) that underscore their potential. Also, pAbs developed against murine cancer cells like hepatocellular carcinoma (HCC), heterotopic syngeneic melanoma model (SKCM), and colorectal carcinoma (CRC) have demonstrated impressive dose-dependent activities in vitro, achieving up to 100% cytotoxicity against target cells.

Therefore, their ability to effectively target and lyse cancer cells while minimizing damage to healthy cells aligns with the increasing focus on precision medicine and targeted therapies. Hence, the increasing usage of antibodies in preclinical models for research purposes emphasizes their growing role in therapeutic applications, driving demand within the mammalian polyclonal IgG antibodies market.

Moreover, the mammalian polyclonal IgG antibodies market is witnessing rapid growth, driven by innovations in antibody modification techniques that enhance the versatility and application of these antibodies. For instance, a study published in Antibody Therapeutics in July 2024 demonstrated the successful modification of goat antibodies targeting green fluorescent protein (GFP) and Chinese hamster ovarian (CHO) phospholipase B-like 2 (PLBL2). Through a systematic three-step process, the antibodies were labeled at the N-glycosylation site of the Fc domain, ensuring site-specific modification that maintained antigen-binding properties. The use of techniques like capillary western blotting on the Wes system confirmed that these modifications did not interfere with antibody performance.

Such advancements underscore the potential for applying similar modifications to antibodies from other mammalian species, broadening the market for specialized polyclonal IgG antibodies. Thus, it is expected to further propel the growth of the mammalian polyclonal IgG antibodies market.

Additionally, the mammalian polyclonal IgG antibodies market continues to experience rapid growth, driven by expanding capabilities in antibody-drug conjugate (ADC) development and manufacturing. For instance, in December 2023, Piramal Pharma Solutions (PPS) expanded its ADC manufacturing facility in Grangemouth with a GBP 45 million (USD 59 million) investment, increasing the site’s capacity by two new ADC manufacturing suites. This development enhanced Piramal’s capabilities and strengthened the mammalian IgG antibodies market by supporting the production of high-quality ADCs that rely on these antibodies for targeted therapeutic action.

Therefore, increasing application of mammalian polyclonal IgG antibodies, advancements in antibody modification, and growing infrastructure investments in ADC manufacturing are driving market expansion. However, the high production costs and regulatory challenges restrain market growth.

Mammalian Polyclonal IgG Antibody Market Trends

Pharmaceutical and Biotechnology Companies Segment Expected to Witness Significant Growth Over the Forecast Period

Mammalian Polyclonal IgG Antibody Industry Segmentation

Mammalian polyclonal IgG antibodies are antibodies produced by mammals' immune systems in response to an antigen. These antibodies are generated by different B-cell clones, resulting in a mixture of antibodies that recognize and bind to multiple epitopes on a single antigen.

The mammalian polyclonal IgG antibodies market is segmented by type, product, application, end user, and geography. By type, the market is segmented into goat, rabbit, horse, mouse, and other types (birds and bats, among others). By product, the market is segmented into cardiac markers, metabolic markers, renal markers, and other products (cancer markers and neurological markers, among others). By application, the market is segmented into ELISA, immunoturbidimetry, antibody identification, immunoelectrophoresis, immunohistochemistry, immunocytochemistry, and western blotting. By end user, the market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, hospitals, and diagnostic centers. By geography, the market is segmented into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The report also offers the market sizes and forecasts for 17 countries across major regions. For each segment, the market sizing and forecasts have been done on the basis of value (USD).